CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acquisition of IMPATH validates this trend and promises to bring more change to […]
New Competitors Line Up In Oncology Marketplace
Genzyme is the latest company to invest big bucks in oncology diagnostics
- By Robert Michel
- > From the Volume XI No. 4 - March 15, 2004 Issue
- Tags: ameripath, anatomic pathologist, Anatomic pathology, anatomic pathology market, anatomic pathology services, cancer testing, cap, dark report, diagnostic testing, diagnostics market, dianon systems, healthcare information systems, healthcare it, Histology, impac, informatics, lab test, lab tests, laboratory information, laboratory information system, national pathology lab, path lab, pathologists, pathology companies, Pathology group, pathology groups, pathology lab, pathology labs, pathology market, pathology service, pathology services, pathology specimen, pathology specimens, pathology test, pathology testing, tamtron, testing for cancer, the dark report
